Q-omics provides the consensus-scored H3-2 profile across patient tissues and cancer cell-line models. H3-2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, H3-2 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, H3-2 RNA expression shows 16,612 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KIRC, and THYM as cancer lineages where H3-2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for H3-2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes H3-2 survival associations across molecular data types. H3-2 RNA expression shows survival associations in the most cancer types (24), followed by mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible H3-2 RNA expression–survival associations across cancer types. High H3-2 expression shows unfavorable associations in UVM, THCA, STAD, KICH, MESO and COAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for H3-2 RNA expression.
This table summarizes H3-2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for H3-2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. H3-2 shows lower tumor expression in UCEC and PRAD and higher tumor expression in KIRC and LUAD. The KIRC box plot shows higher H3-2 RNA expression in tumor versus normal tissue (log2 FC = +0.207, t-test p < 0.001).
This table shows molecular features associated with H3-2 in patient tissues and cancer cell lines. In patient samples, H3-2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, H3-2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC.
